Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

71.77 -8.09 (-10.13%)
Streaming Delayed Price Updated: 2:20 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗
This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗
This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Apogee Therapeutics Stock Triumphed on Thursday ↗
The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort. 
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Gold Falls 1%; ProKidney Shares Spike Higher ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips 1%; Mustang Bio Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
News headline image
What's going on in today's pre-market session ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Plunge This Month ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial ↗
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing. 
Via Benzinga
News headline image
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Apogee Therapeutics Stock Trading Higher On Monday? ↗
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent. 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024 ↗
APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
News headline image
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 ↗
APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter ↗
Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors. 
Via InvestorPlace
News headline image
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.